<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157348</url>
  </required_header>
  <id_info>
    <org_study_id>D3253C00001</org_study_id>
    <secondary_id>2019-001832-77</secondary_id>
    <nct_id>NCT04157348</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.</brief_title>
  <acronym>MANDARA</acronym>
  <official_title>A Randomized, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week&#xD;
      Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300&#xD;
      mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA&#xD;
      on corticosteroid therapy with or without stable immunosuppressive therapy.&#xD;
&#xD;
      All patients who complete the 52-week double-blind treatment period on IP may be eligible to&#xD;
      continue into an open label extension (OLE) period. The OLE period is intended to allow each&#xD;
      patient at least 1 year of treatment with open-label benralizumab 30 mg administered SC&#xD;
      (earlier enrolled patients may therefore be in the OLE for longer than 1 year).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2019</start_date>
  <completion_date type="Anticipated">January 27, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who are in remission at both weeks 36 and 48</measure>
    <time_frame>36 and 48 weeks</time_frame>
    <description>Patients must be in remission at both of these timepoints of weeks 36 and 48.&#xD;
Main definition: Remission is defined as BVAS=0 and OCS dose ≤ 4mg/day. Supportive definition: Remission is defined by BVAS =0 and OCS dose ≤ 7.5 mg/day.&#xD;
Analysis will be repeated based on main and supportive remission definitions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients in each category of accrued duration of remission</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>The categories of accrued duration of remission are: 0 wk, &gt;0 to &lt;12 wk, 12 to &lt;24 wk, 24 to &lt;36 wk, ≥36 wk. Analysis will be repeated based on main and supportive remission definitions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomisation to first EGPA relapse</measure>
    <time_frame>During first 52 weeks</time_frame>
    <description>Relapse is defined as any of the following:&#xD;
Active vasculitis (BVAS &gt;0); OR&#xD;
Active asthma symptoms and/or signs with a corresponding worsening in ACQ-6 score; OR&#xD;
Active nasal and/or sinus disease, with a corresponding worsening in at least one of the sino-nasal symptom questions&#xD;
warranting any of the following:&#xD;
an increase of OCS therapy (&gt;4mg prednisolone total daily dose or equivalent);&#xD;
an increased dose or addition of an immunosuppressive agent;&#xD;
Hospitalisation related to EGPA worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients in each category of average daily prednisolone/prednisone dose during weeks 48 through 52</measure>
    <time_frame>48 through 52 weeks</time_frame>
    <description>The categories of average daily prednisolone/prednisone dose are: 0; &gt;0 to ≤4 mg; &gt;4 to ≤7.5 mg and &gt; 7.5 mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized relapse rate</measure>
    <time_frame>Over first 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who have achieved remission within the first 24 weeks and remained in remission for remainder of the double-blind treatment period</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Analysis will be repeated based on main and supportive remission definitions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in VDI</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Vasculitis Damage Index (VDI)&#xD;
Vasculitis Damage Index measures accrued damage across 11 organ systems since diagnosis. Total score is sum of all systems and ranges from 0 to 64 with higher scores indicating more damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BVAS</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Birmingham Vasculitis Activity Score (BVAS)&#xD;
Birmingham Vasculitis Activity Score (BVAS) measures vasculitis disease activity across 9 organ systems. Total score is sum of the weighted organ scores and ranges from 0 to 63 with higher scores indicating higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pulmonary function</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>As measured by Forced vital capacity (FVC), unit L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pulmonary function</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>As measured by Forced Expiratory Volume during first second (FEV1), unit L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ACQ-6</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Asthma Control Questionnaire (6-item version) (ACQ-6 )&#xD;
The 6 items in ACQ-6 have a 7-point scale ranging from 0=no impairment to 6=maximum impairment. The ACQ-6 score is calculated by taking the mean of the 6 equally weighted items ranging from 0=well controlled to 6=extremely well controlled. Higher scores indicate worse disease control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sino-nasal symptoms (SSQ)</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Sino-nasal Symptoms Questionnaire (SSQ)&#xD;
SSQ captures 5 different sino-nasal symptoms over the previous week as scored as none, mild, moderate, severe, or very severe. Higher scores indicate greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SNOT-22</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Sino-nasal Outcome Test-22 (SNOT-22)&#xD;
The 22 items in SNOT-22 have a 6-point scale ranging from 0=no problem to 5=problem as bad as it can be. The total score is the sum of item scores and has a range from 0 to 110. Higher scores indicate poorer outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SF-36v2</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Short Form 36-item health survey (version 2, acute recall) (SF-36v2)&#xD;
The short form 36-item health survey, version 2 (SF-36v2) is a 36-item, self-report survey of functional health and well-being. The assessment yields 8-domain profile consisting of the following: Physical functioning (PF), role limitations due to physical health (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH). Psychometrically-based physical and mental health component summary scores (PCS and MCS, respectively) are computed from subscale scores to give a broader metric of physical and mental health-related quality of life. The score range is 0 to 100 with higher scores indicating better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PGIS</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Patient Global Impression of Severity (PGIS)&#xD;
PGIS is a 6-point categorical response scale ranging from 0=no symptoms to 6= very severe symptoms. Higher scores indicate worse severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in WPAI</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Work productivity and Activity Impairment Questionnaire (WPAI)&#xD;
WPAI consists of 6 questions regarding absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment. WPAI outcomes are scored as impairment percentages, with a higher percentage indicating greater impairment and less productivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood eosinophil counts</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of PGIC responders at each weekly assessment</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Patient Global Impression of Change (PGIC)&#xD;
Patient Global Impression of Change (PGIC) measures the patient´s overall impression of response to treatment since the initial dose using a 7-point scale ranging from &quot;much better&quot;, &quot;about the same&quot; to &quot;much worse&quot;. Lower scores indicate better health status.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Numbers of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Minimum of 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in systolic and diastolic blood pressure</measure>
    <time_frame>Minimum of 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in pulse rate</measure>
    <time_frame>Minimum of 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in hematology parameters of hemoglobin, leukocytes, lymphocytes, monocytes, basophils, eosinophils, neutrophils, and platelets</measure>
    <time_frame>Minimum of 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in clinical chemistry parameters of Alanine Aminotransferase (ALT), alkaline phosphatase, Aspartate Aminotransferase (AST), creatinine kinase, indirect and total bilirubin, creatinine and glucose</measure>
    <time_frame>Minimum of 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in QT Interval Corrected by Fridericia's Method (QTcF)</measure>
    <time_frame>Minimum of 52 weeks</time_frame>
    <description>Triplicate measurements of 12-lead electrocardiograms recorded at rest.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum benralizumab concentration as a measure of pharmacokinetics</measure>
    <time_frame>Minimum of 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Anti-drug antibodies (ADA) titers as measure of immunogenicity</measure>
    <time_frame>Minimum of 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cumulative OCS use</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Total OCS use (measured in mg) as measured by sum of all daily doses during the 52-week double-blind period.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of EGPA related hospitalisations</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>ICU (Intensive Care Unit) days</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of EGPA related ER visits</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of EGPA related outpatient visits</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of EGPA related procedures/tests (by specific procedure/test)</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Eosinophilic Granulomatous Vasculitis</condition>
  <arm_group>
    <arm_group_label>Benralizumab arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1x benralizumab SC injection + 3x placebo to mepolizumab SC injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mepolizumab arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3x mepolizumab SC injections + 1x placebo to benralizumab SC injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Benralizumab</intervention_name>
    <description>30 mg/mL solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC)</description>
    <arm_group_label>Benralizumab arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mepolizumab</intervention_name>
    <description>3x100 mg vials of powder for solution for injection reconstituted into 3 separate 1 mL syringes for administration on each dosing occasion. Injection volume per syringe is 1 mL. Mepolizumab active solution will be administered subcutaneously (SC)</description>
    <arm_group_label>Mepolizumab arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo to Mepolizumab</intervention_name>
    <description>Matching placebo: 0.9% sodium chloride, solutions for injection in 1mL syringes (3 syringes will be used on each dosing occasion). Injection volume per syringe is 1mL. Placebo to Mepolizumban will be administered subcutaneously (SC)</description>
    <arm_group_label>Benralizumab arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo to Benralizumab</intervention_name>
    <description>Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC)</description>
    <arm_group_label>Mepolizumab arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects age 18 years or older.&#xD;
&#xD;
          2. EGPA diagnosis based on history or presence asthma and eosinophilia (&gt;1.0x10^9/L&#xD;
             and/or &gt;10% of leucocytes) and at least 2 of; biopsy with eosinophilic vasculitis or&#xD;
             perivascular/granulomatous inflammation; mono-or polyneuropathy, non-fixed pulmonary&#xD;
             infiltrates, sino-nasal abnormality; cardiomyopathy; glomerulonephritis; alveolar&#xD;
             haemorrhage; palpable purpura; anti neutrophil cytoplasmic anti-body (ANCA) positivity&#xD;
             (Myeloperoxidase or proteinease 3).&#xD;
&#xD;
          3. History of relapsing (at least 1 confirmed EGPA relapse within last 2 years and &gt; 12&#xD;
             weeks prior to screening, or refractory (failure to attain remission, defined as&#xD;
             BVAS=0 and oral corticosteroid (OCS) dose &lt;=7.5 mg/day of prednisolone or equivalent,&#xD;
             following standard induction regimen for at least 3 months and within 6 months prior&#xD;
             to screening, or recurrence of symptoms upon OCS tapering at any dose of ≥7.5 mg/day&#xD;
             prednisolone or equivalent. If induction with glucocorticoidsalone, patient must have&#xD;
             failed to attain remission after 3 months and the glucocorticoid dose must be ≥15&#xD;
             mg/day prednisolone or equivalent for the 4 weeks prior to randomization.&#xD;
&#xD;
          4. Must be on a stable dose of oral prednisolone or prednisone of ≥7.5 mg/day (but not&#xD;
             &gt;50mg/day) for at least 4 weeks prior to randomization. Stable doses of OCS other than&#xD;
             prednisolone or prednisone may be acceptable, but must be discussed with the&#xD;
             AstraZeneca study physician.&#xD;
&#xD;
          5. If receiving immunosuppressive therapy (excluding cyclophosphamide) the dose must be&#xD;
             stable for the 4 weeks prior to randomization and during the study (dose reductions&#xD;
             for safety reasons will be permitted).&#xD;
&#xD;
          6. QTc(F)&lt;450 msec or QTc(F)&lt;480 msec for patients with bundle branch block.&#xD;
&#xD;
          7. Females of childbearing potential must use an acceptable method of birth control from&#xD;
             signing the informed consent for at least 12 weeks after the last study drug&#xD;
             administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis&#xD;
             (MPA).&#xD;
&#xD;
          2. Organ or life-threatening EGPA &lt; 3 months prior to screening and through&#xD;
             randomisation.&#xD;
&#xD;
          3. Currently pregnant or breastfeeding, or planning to become pregnant during study&#xD;
             participation.&#xD;
&#xD;
          4. Current malignancy or history of malignancy, unless received curative therapy &gt;5 years&#xD;
             ago, or &gt;1 year ago for basal cell carcinoma, localized squamous cell carcinoma of the&#xD;
             skin or in situ carcinoma of the cervix.&#xD;
&#xD;
          5. An untreated or refractory helminth parasitic infection &lt; 24 weeks prior to screening.&#xD;
&#xD;
          6. Unstable liver disease.&#xD;
&#xD;
          7. Severe or clinically significant, uncontrolled cardiovascular disease.&#xD;
&#xD;
          8. Other concurrent disease that may put the patient at risk, or may influence the&#xD;
             results of the study, or the patients' ability to complete entire duration of the&#xD;
             study.&#xD;
&#xD;
          9. Chronic or ongoing infectious disease requiring systemic antiinfective treatment.&#xD;
&#xD;
         10. Known immunodeficiency disorder or positive HIV test.&#xD;
&#xD;
         11. Prior receipt of mepolizumab, reslizumab, dupilumab or benralizumab. Receipt of&#xD;
             intravenous/intramuscular/subcutaneous corticosteroids within 4 weeks prior to&#xD;
             randomization, receipt of omalizumab within 130 days prior to screening, rituximab&#xD;
             within 6 months prior to screening (or B-cells not recovered), interferon-α or&#xD;
             alemtuzumab within 6 months prior to screening, receipt of anti-tumor necrosis factor&#xD;
             therapy within 12 weeks prior to screening, receipt of of any other marketed or&#xD;
             investigational biologic products within 4 months or 5 half-lives prior to screening,&#xD;
             whichever is longer . Or receipt of any investigational non-biologic product within 30&#xD;
             days or 5 half-lives prior to screening (V1), whichever is longer, prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Wechsler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health, 1400 Jackson St Denver, CO 80206</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63156</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denison</city>
        <state>Texas</state>
        <zip>75020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>PARIS cedex 18</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suresnes Cedex</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kirchheim</city>
        <zip>73230</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashkelon</city>
        <zip>7830604</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rehovot</city>
        <zip>7661041</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torino</city>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiba-shi</city>
        <zip>260-0877</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kita-gun</city>
        <zip>761-0793</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sagamihara-shi</city>
        <zip>228-0815</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>SE19RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D3253C00001&amp;amp;attachmentIdentifier=f1ea6ab0-2192-44ba-9851-0549ffaf44a1&amp;amp;fileName=MANDARA_Poster_V2.0.pdf&amp;amp;versionIdentifier=</url>
    <description>This is a poster.</description>
  </link>
  <link>
    <url>http://www.mandarastudy.com/</url>
    <description>A website on the Mandara study.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 29, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Benralizumab</keyword>
  <keyword>Inhaled corticosteroids</keyword>
  <keyword>Eosinophilic Granulomatous Vasculitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Churg-Strauss Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benralizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

